Role of virus strain dm conventional and enhanced measles plaque neutralization test

Albrecht, Paul; Herrmann, Kenneth L.; Burns, Gary R.

doi:10.1016/0166-0934(81)90062-8

Cited by 180 publications

(85 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PNT is a very sensitive and functional method whereby the antibodies neutralize the capacity of the virus to infect cells [20]. Neutralizing antibodies are commonly assumed to correlate with protection.…”

Section: Evaluation Of Eia Results By Pntmentioning

confidence: 99%

Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

Tischer

Andrews²,

Kafatos³

et al. 2007

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYThe aim of the European Sero-Epidemiology Network is to establish comparability of the serological surveillance of vaccine-preventable diseases in Europe. The designated reference laboratory (RL) for measles, mumps, rubella (MMR) prepared and tested a panel of 151 sera by the reference enzyme immunoassay (rEIA). Laboratories in 21 countries tested the panel for antibodies against MMR using their usual assay (a total of 16 different EIAs) and the results were plotted against the reference results in order to obtain equations for the standardization of national serum surveys. The RL also tested the panel by the plaque neutralization test (PNT). Large differences in qualitative results were found compared to the RL. Well-fitting standardization equations with R 2 o0 . 8 were obtained for almost all laboratories through regression of the quantitative results against those of the RL. When compared to PNT, the rEIA had a sensitivity of 95 . 3%, 92 . 8% and 100 % and a specificity of 100%, 87 . 1 % and 92 . 8 % for measles, mumps and rubella, respectively. The need for standardization was highlighted by substantial inter-country differences. Standardization was successful and the selected standardization equations allowed the conversion of local serological results into common units and enabled direct comparison of seroprevalence data of the participating countries.

show abstract

Section: Evaluation Of Eia Results By Pntmentioning

confidence: 99%

Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

Tischer

Andrews²,

Kafatos³

et al. 2007

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…In an adapted form of the PRN test [22], the challenge virus was incubated with a doubling dilution series of the test serum from 1/4 to 1/ 128. After 90 min at room temperature, the virus-antibody mixture was titrated in a plaque assay using Vero cells in 24-well plastic plates [23].…”

Section: Vaccinated Mothersmentioning

confidence: 99%

A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

Brugha¹,

Ramsay²,

Forsey

et al. 1996

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYMaternal, cord and infant measles antibody levels were measured and compared in a group of 411 vaccinated mothers and 240 unvaccinated mothers, and their babies, between 1983 and 1991. Maternal and cord sera were tested by haemagglutination inhibition and/or enzymelinked immunosorbent assay, and plaque reduction neutralization tests were also used to test infant sera. Geometric mean titres were significantly higher in the unvaccinated than in the vaccinated mothers (P < 0-001). Infants born to mothers with a history of measles had higher antibody levels at birth than infants of vaccinated mothers and, although the difference narrowed over time, continued to have higher levels up to 30 weeks of age. Between 5 and 7 months of age significantly more of the children of vaccinated mothers had plaque reduction neutralization antibody levels below that which would interfere with vaccination. As the boosting effect of circulating natural measles disappears, earlier measles vaccination may need to be considered, perhaps as part of a two-dose policy.

show abstract

“…Subjects provided blood for antibody measurements prior to immunization and on days 14, 28 and 90. PRN titers were measured as previously described, 11 using an adaptation of the method described by Albrecht et al 12 Samples were tested in parallel with the 2 nd WHO International Measles Reference Serum (66/202). Seroconversion was defined as a 4-fold rise in antibody titers after vaccination.…”

Section: Methodsmentioning

confidence: 99%

A Clinical Study to Assess the Safety and Immunogenicity of Attenuated Measles Vaccine Administered Intranasally to Healthy Adults

Simon¹,

Pasetti²,

Viret³

et al. 2007

Human Vaccines

View full text Add to dashboard Cite

Background. Despite the availability of a safe and effective vaccine for over four decades, measles remains one of the most common infectious disease killers of children in the world. Mucosal administration of currently licensed measles vaccine has been proposed to address issues of needle safety and improve vaccine uptake.Methods. Healthy adult volunteers were randomized to receive live-attenuated monovalent measles virus vaccine (Moraten Berna) via the standard subcutaneous (SQ) or the experimental intranasal (IN) route in a randomized, double-masked fashion. Safety, reactogenicity, immunogenicity, and shedding were assessed.Results. Safety, reactogenicity, and viral shedding were not significantly different in the two study groups. Immunogenicity was markedly lower in the group of volunteers that received vaccine via the IN route. Plaque reduction neutralization (PRN) geometric mean titers (GMT) were 125 (95% confidence interval [CI] 68-228) milli International Units per milliliter (mIU/mL) on day 28 in recipients of IN vaccine versus 645 (95% CI 468-889) mIU/mL in recipients of vaccine SQ; p<0.001 by Mann-Whitney Rank Sum. 50% of measles non-immune individuals mounted titers above the protective threshold of PRN 200 mIU/mL after IN administration versus 100% of volunteers who received the vaccine SQ.Conclusion. Intranasal administration of live-attenuated measles vaccine was safe and well tolerated, but failed to mount significant immune responses when compared to subcutaneous administration. It is possible that higher doses or smaller particle size are necessary for successful intranasal measles vaccination and boosting.

show abstract

Role of virus strain dm conventional and enhanced measles plaque neutralization test

Cited by 180 publications

References 19 publications

Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

A Clinical Study to Assess the Safety and Immunogenicity of Attenuated Measles Vaccine Administered Intranasally to Healthy Adults

Contact Info

Product

Resources

About